About AVIA Biosystems
AVIA Biosystems is a company based in Norton (United States) founded in 2012 was acquired by Unchained Labs in June 2015. AVIA Biosystems has raised $1.1 million across 5 funding rounds from investors including HHS and Unchained Labs. AVIA Biosystems offers products and services including ICD Systems and Model 2304 ICD Systems. AVIA Biosystems operates in a competitive market with competitors including Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
- Headquarter Norton, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avia Biosystems, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.1 M (USD)
in 5 rounds
-
Latest Funding Round
$207.38 K (USD), Grant
Mar 01, 2015
-
Investors
HHS
& 1 more
-
Employee Count
Not available
-
Acquired by
Unchained Labs
(Jun 04, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AVIA Biosystems
AVIA Biosystems offers a comprehensive portfolio of products and services, including ICD Systems and Model 2304 ICD Systems.
Measures protein denaturation with minimal samples for biologics testing.
Screens buffers and excipients for protein stability optimization.
Funding Insights of AVIA Biosystems
AVIA Biosystems has successfully raised a total of $1.1M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $207.38 thousand completed in March 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AVIA Biosystems
AVIA Biosystems has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Unchained Labs.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Multiplex protein stability platform for biologics is developed.
|
Locked | Locked | Locked |
Investor details for AVIA Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AVIA Biosystems
Investment portfolio details for AVIA Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AVIA Biosystems
Detailed financials for AVIA Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avia Biosystems Comparisons
Peer comparison for AVIA Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AVIA Biosystems
AVIA Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein-based assays are developed for life science research.
|
|
| Locked | Locked | Locked |
A proteomics platform is developed for analyzing the human proteome.
|
|
| Locked | Locked | Locked |
Peptide-based therapeutics are developed for cancers and immune disorders.
|
|
| Locked | Locked | Locked |
Proteomics services are delivered via discovery and targeted platforms.
|
|
| Locked | Locked | Locked |
Digital platform transforming the delivery of biologic medicines
|
|
| Locked | Locked | Locked |
Provider tools to help researchers with protein analysis
|
Detailed competitors of AVIA Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avia Biosystems
Complete news archive for AVIA Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AVIA Biosystems
AVIA Biosystems was founded in 2012.
AVIA Biosystems is headquartered in Norton, United States.
AVIA Biosystems is a funded company, having raised a total of $1.1M across 5 funding rounds to date.
The ICD system makes possible the routine measurement of protein stability under denaturing conditions. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The company has a device developed to facilitate the formulation of biologics in a safe and stable form, the system uses intrinsic or extrinsic fluorescence to monitor the conformational changes associated with protein unfolding (denaturation) and automatically generates complete protein stability curves. In pharmaceutical discovery and development settings, large numbers of constructs or formulations need to be rapidly and easily compared (rank-ordered) for stability. For these applications, automated chemical denaturation provides the most powerful and convenient means to assess protein stability.
AVIA Biosystems's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
AVIA Biosystems offers ICD Systems and Model 2304 ICD Systems.
AVIA Biosystems has 2 investors. Key investors include HHS, and Unchained Labs.